Inhibition of leukotrienes and their potential role in type 1 diabetes pathogenesis: implications for montelukast as a therapeutic agent: a case report
2024

Montelukast's Role in Reducing Insulin Needs for Type 1 Diabetes

Sample size: 1 publication Evidence: low

Author Information

Author(s): Fatulla Pavel, Ström Ingela, Lingblom Christine, Lind Marcus

Primary Institution: NU Hospital Group, University of Gothenburg

Hypothesis

Can montelukast reduce insulin requirements in patients with type 1 diabetes?

Conclusion

Montelukast may help reduce insulin needs in type 1 diabetes patients, suggesting a potential therapeutic role.

Supporting Evidence

  • Montelukast treatment led to a 60.5% reduction in insulin requirements.
  • After a second course of montelukast, insulin needs decreased by 87.9%.
  • The patient reported stable glucose levels despite reduced insulin doses.

Takeaway

A man with type 1 diabetes found that taking montelukast helped him use less insulin, which is surprising because it's usually for asthma.

Methodology

The case report details the patient's insulin usage before, during, and after montelukast treatment, along with blood glucose monitoring.

Potential Biases

Individual responses to medications can vary significantly, and the absence of control groups complicates interpretation.

Limitations

The findings are based on a single case, limiting generalizability and the ability to establish cause and effect.

Participant Demographics

A 55-year-old male with Latent Autoimmune Diabetes in Adults (LADA).

Digital Object Identifier (DOI)

10.3389/fcdhc.2024.1494470

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication